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Objective: To investigate the underlying pathophysiology in the urothelium of different lower urinary
tract diseases (LUTDs) and in patients with overactive bladder (OAB) or hypersensitive bladder (HSB),
including chronic inﬂammation, barrier proteins, and sensory functional receptors.
Materials and Methods: A total of 156 patients, including 14 with idiopathic OAB, 11 with detrusor
overactivity and inadequate contractility (DHIC), 19 with end-stage renal disease (ESRD) and HSB, 26
with spinal cord injury (SCI) and detrusor overactivity (DO), 23 with bladder outlet obstruction (BOO)
and DO, 19 with diabetes mellitus (DM) and OAB, 20 with interstitial cystitis (IC), and 24 with ketamine
cystitis (KC) were investigated for urothelial dysfunction and sensory protein expressions. Twenty
control patients without LUTD were invited and separated into two groups for comparative studies. All
participants had urodynamically proven DO or increased bladder sensation on video urodynamic studies.
Urothelial dysfunction and functional receptor expressions were investigated and compared between
patients with LUTD and controls.
Results: All patient subgroups had signiﬁcant increases in mast cell activation and apoptotic cell counts
and a decrease in E-cadherin expression. P2X3 expression was signiﬁcantly decreased in DHIC but was
increased in BOO/DO. Urothelial M3 expression was signiﬁcantly increased in patients with OAB, BOO/
DO, DM/OAB, and KC. M2 expression was signiﬁcantly decreased in DHIC but increased in patients with
BOO/DO. b3-AR expression was signiﬁcantly decreased in patients with OAB and increased in patients
with DHIC, ESRD/HSB, DM/OAB, and KC. Patients with OAB and BOO/DO had signiﬁcantly increased M2/
b3-AR. Lower M2/b3-AR was associated with lower voiding efﬁciency and large postvoid residual (PVR)
in DHIC, ESRD/HSB, and SCI/neurogenic detrusor overactivity (NDO).
Conclusion: Patients with OAB or HSB showed increased urothelial inﬂammation and lower barrier
protein expression. Increased M3/b3-AR or M2/b3-AR in the urothelium was associated with OAB,
whereas decreased M3/b3-AR or M2/b3-AR was associated with poor voiding efﬁciency and large PVR in
LUTD.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The urothelium of the urinary bladder plays a signiﬁcant role in
bladder sensation during urine storage and mediates detrusor
contraction during voiding. The urothelium detects physiological
and chemical stimuli and releases various signaling molecules.1ddhist Tzu Chi General Hos-
an.
m.tw, hck@tzuchi.com.tw
ociation. Published by Elsevier Ta
, Kuo H-C, Urothelial dysfunc
r, Urological Science (2016),Under several conditions, the urothelial barrier is disrupted and
results in a cascade of events in the bladder, leading to symptoms of
lower urinary tract diseases (LUTD), such as in interstitial cystitis
(IC) and ketamine-related cystitis (KC).2
Several LUTDs, such as bladder outlet obstruction (BOO), IC, KC,
spinal cord injury (SCI) with neurogenic bladder, and systemic
diseases, such as diabetes mellitus (DM), end-stage renal disease
(ESRD), and congestive heart failure may cause overactive bladder
(OAB) or hypersensitive bladder (HSB). There are several similar-
ities in serum biomarkers and bladder urothelial histopathologies
in these LUTDs.3 Biomarkers, such as urinary nerve growth factor oriwan LLC. This is an open access article under the CC BY-NC-ND license (http://
tion and sensory protein expressions in patients with urological or
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benign prostatic hyperplasia and lower urinary tract symptoms
(LUTS), suggesting chronic inﬂammation is involved in these
LUTDs.4e7 Previous studies have shown mast cell inﬁltration in
both OAB and IC bladder epithelia, suggesting that suburothelial
inﬂammationwas involved in IC as well as in OAB. Nonetheless, the
adhesion protein E-cadherin and tight junction protein zonula
occludens-1 (ZO-1) expressions were decreased only in IC.8 The
urothelial dysfunction is likely to be a part of the pathogenesis for
the LUTDs that possess bladder hypersensitivity or overactivity.9
Altered regulation of urothelial homeostasis in IC is likely to
cause epithelial dysfunction, activation of mast cells, neurogenic
inﬂammation, and autoimmunity.9e11 IC bladder biopsies showed
abnormal expression of uroplakin, chondroitin sulfate, and ZO-1,
strongly suggestive of abnormal cell differentiation in bladders
with IC.12 Investigation of the relationships between chronic
inﬂammation and urothelial dysfunction, such as urothelial
apoptosis, expression of junction proteins, and inﬂammatory re-
actions in the suburothelium, could advance our understanding of
the pathophysiology of bladder hypersensitivity in LUTDs.13
Bladder urothelium expresses all subtypes of muscarinic re-
ceptors. M3 receptors are primarily responsible for detrusor
contraction. M2 receptors have a role in mediating indirect con-
tractions or inhibition of detrusor relaxation.14 In the human
detrusor muscle, M2 and M3 receptors are predominant. Although
the density of M2 receptors is three times that of M3 receptors,15
M3 receptors mediate detrusor contraction in vitro.16 In M3
knockout mice study, 95% of bladder strips contractility induced by
carbachol was found to be mediated by M3 receptors.17 Evidence
also suggests that antimuscarinic drugs affect muscarinic receptors
within the urothelium and on bladder sensory nerves.18,19 In a state
of bladder pathology, muscarinic receptors change in the detrusor,
prejunctional nerve ending, and in the urothelium, affecting
bladder afferent nerves and smooth muscle.20
Distension-evoked adenosine triphosphate (ATP) release from
the bladder urothelium plays a crucial role in the transmission of
the sensation of fullness and pain and induces reﬂex changes in the
bladder.21 Bladder pathology often results in augmented ATP
release from the urothelium, causing excitation of purinergic re-
ceptors (P2X) on the sensory ﬁbers.22 Activation of cholinergic re-
ceptors in the feline epithelium cells facilitates ATP release and
activates adjacent afferent nerves near myoﬁbroblasts, which re-
sults in sensory urgency.23 The immunoreactivity of M2, M3, and
P2X3 receptors was greatest in the urothelium of rats with BOO
compared with the control rats.24
Beta-3 adrenoceptors (b3-AR) are abundant in the detrusor of
the urinary bladder and play a major role in detrusor relaxation
during the storage phase of bladder function.25 The b3-ARs promote
urine storage by inducing detrusor relaxation in animal and human
bladders.26 In humans, the b3-ARs are recognized as the predomi-
nant b-receptor subtype in the urinary bladder, representing 97% of
total b-adrenoceptor mRNA expression in the bladder.27 b3-AR ag-
onists relax the detrusor smooth muscle during the bladder storage
phase and increase bladder capacity.28 b3-ARs in the human uro-
thelium appear to be functional such that receptor density changes
in disease states alter bladder storage function.29
This study aims to investigate the underlying pathophysiology
in the urothelium of several LUTDs and systemic diseases with OAB
or HSB. We speculate that chronic inﬂammation and altered sen-
sory protein expression in the bladder urothelium is involved in the
pathogenesis of OAB and HSBwith systemic diseases. The urothelial
dysfunction markers (apoptosis, mast cell activity, E-cadherin, and
ZO-1) and sensory receptors in the urothelium (M2, M3, b3-AR, and
P2X3) were explored to deﬁne the underlying pathophysiology of
the OAB/HSB symptoms in these LUTDs.Please cite this article in press as: Ong H-L, Kuo H-C, Urothelial dysfunc
systemic diseases and hypersensitive bladder, Urological Science (2016),2. Materials and methods
2.1. Patients
The patients investigated in this study were selected from the
Tzu Chi General Hospital Department of Urology, Hualien, Taiwan.
The enrolled patients included: (1) 20 control patients with su-
perﬁcial bladder cancer without LUTS, stress urinary incontinence
undergoing anti-incontinence surgery, or microscopic hematuria
undergoing ureteroscopic examination; the 20 control patients
were separated into two groups for comparative study with
different LUTD subgroups; (2) patients with idiopathic OAB; (3)
patients with detrusor overactivity and inadequate contractility
(DHIC); (4) patients with ESRD with HSB; (5) patients with SCI and
DO; (6) patients with BOO and urodynamic detrusor overactivity
(DO) due to benign prostatic hyperplasia; (7) patients with DM and
OAB; (8) patients with IC and HSB; and (9) patients with KC and
HSB. All bladder specimens were obtained at cystoscopic exami-
nations or transurethral surgeries to determine a diagnosis or
treatment procedure.
The diagnosis of LUTDs was based on the recommendations of
the International Continence Society. DHIC was deﬁned when
patients had urodynamic DO with low voiding pressure and post-
void residual (PVR) greater than 33% of the cystometric bladder
capacity (CBC).30
The research ethics committee of Buddhist Tzu Chi General
Hospital approved this study (IRB: TCGH 101-061). Each patient
was informed about the study rationale and procedures and writ-
ten informed consent was obtained before any bladder procedure.
Bladder biopsies at the posterior wall were performed before any
cystoscopic procedure and from controls after anti-incontinence
procedures.
2.2. Bladder tissue study
Four bladder biopsies were obtained from the posterior wall
about 2 mm above the ureteral oriﬁce, and only bladder mucosa
was taken. One of the bladder biopsy specimens was sent to the
pathology department for hematoxylin and eosin staining to
exclude the possibility of carcinoma in situ. The other specimens
were embedded in optimum cutting temperature medium and
were stored frozen at 80C for further investigations.
2.3. Immunoﬂuorescence staining
The urinary bladder specimens were immersed and ﬁxed for
1 hour in an ice-cold solution of 4% formaldehyde in phosphate-
buffered saline (PBS; pH 7.4). Next, they were rinsed with ice-
cold PBS containing 15% sucrose for 12 hours. Biopsy specimens
were embedded in optimum cutting temperature medium and
stored at 80C. Four sections per specimen were cut using a
cryostat at a thickness of 8 mm and were collected onto new silane
III-coated slides (Muto Pure Chemicals Co., LTD, Tokyo, Japan).
Sections were postﬁxed in acetone at 20C and blocked with
rabbit serum. The sections were incubated overnight at 4C with
primary antibodies to antihuman ki-67 (DakoCytomation
Denmark A/S, Glostrup, Denmark), antihuman E-cadherin (BD
Biosciences, San Diego, CA, USA), antihuman ZO-1 (Invitrogen,
Burlington, Canada), or antihuman tryptase (Chemicon, Temecula,
CA, USA) After rinsing the sections with 0.1% Tween-20 in PBS,
rabbit antimouse-conjugated ﬂuorescein isothiocyanate secondary
antibodies (DakoCytomation Denmark A/S) were applied to the
sections and incubated for 1 hour. Finally, the sections were
counterstained with DAPI (Sigma Chemical Company, St. Louis,
MO, USA). The negative controls included the isotypes of thetion and sensory protein expressions in patients with urological or
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standard deviation of staining intensity and percent positive area
measurements using three randomly chosen hot spots within each
specimen. Immunoﬂuorescence staining images of E-cadherin and
mast cell tryptase were captured using ﬂuorescence microscopy
with a digital imaging system (Zeiss, Oberkochen, Germany). The
distribution and ﬂuorescence intensity of ZO-1 was measured
using a confocal microscope (Zeiss). Expression of E-cadherin and
ZO-1 in the urothelium were quantiﬁed using Image J Software,
which was developed by the National Institutes of Health.31 The
percentages of tryptase-positive mast cells were calculated from
ﬁve consecutive high-power ﬁelds (400) from areas with the
highest density cell inﬁltration.
For Immunohistochemistry (IHC) of b3-AR, the urinary bladder
specimens were ﬁxed and processed for immunohistochemical
analyses as previously described. Sections were incubated over-
night at 4C with an antibody against human b3-AR (Abcam,
Cambridge, UK). Streptavidin-biotin peroxidase complex technol-
ogy (super sensitive Immunohistochemistry detection systems;
BioGenex Laboratories, Fremont, CA, USA) was used. Images were
obtained using a digital imaging system (Zeiss).
The results of immunoﬂuorescence (tryptase) staining were
quantiﬁed by counting the numbers of positive cells/total cells per
unit area (4 mm2) shown as the percentage of positive cells per 100
total cells. Three tissue sections per sample from diseased bladders
and controls were evaluated, and the mean values were used in the
subsequent statistical analyses.
2.4. Terminal deoxynucleotidyl transferase dUTP nick end labeling
assay
The urinary bladder specimens were ﬁxed by immersion for
1 hour in an ice-cold solution of 4% formaldehyde in PBS (pH 7.4).
They were then rinsed with ice-cold PBS containing 15% sucrose for
12 hours. The specimens were embedded in optimum cutting
temperature medium (Miles, Elkhart, IN, USA) and then stored
at 80C. The tissues were cut into 8 mm-thick slices and were
collected onto new silane-III-coated slides. The sections were
incubated with 100 mL of 20 mg/mL proteinase K (Calbiochem,
Darmstadt, Germany) at room temperature for 20 minutes and
washed with PBS. The sections were covered with 100 mL of ter-
minal deoxynucleotidyl transferase (TdT) equilibration buffer
(Calbiochem) and then incubated at room temperature for 30 mi-
nutes. After carefully blotting the 1X TdT equilibration buffer from
the specimens, we applied TdT labeling reaction mixture (Calbio-
chem) onto the specimens and incubated them for 90 minutes at
37C. The positive control, apoptotic HL-60 cells (Calbiochem), was
treated with 1 mg/mL DNase I in Tris-buffered saline/1mM MgSO4
(Promega Corporation, Madison, WI, USA) at room temperature for
20 minutes. The negative control was generated by substituting
dH2O for the TdT enzyme in the reaction mixture. After washing
with PBS, the cells were mounted using Fluorescein-FragEL
mounting media (Calbiochem). The total cell population was visu-
alized using a 330e380 nm ﬁlter for DAPI while the labeled nuclei
were visualized using a standard ﬂuorescein ﬁlter (465e495 nm).
2.5. Western blotting
Western blotting was done to identify sensory proteins in the
urothelium including the muscarinic receptors M2 and M3, b3-AR,
and purinergic receptor P2X3. First, the bladder tissues were ho-
mogenized with liquid nitrogen and the proteins were separated
using lysis buffer with a protease inhibitor cocktail and phospha-
tase inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) for
60 minutes. The soluble proteins were determined using the Bio-Please cite this article in press as: Ong H-L, Kuo H-C, Urothelial dysfunc
systemic diseases and hypersensitive bladder, Urological Science (2016),Rad Protein Assay Dye Reagent Concentrate (Bio-Rad Labora-
tories, Inc., Hercules, CA, USA) by adding 10 mg to 8e16% Precise
Tris-Glycine Gel (Thermo Scientiﬁc, Rockford, IL, USA) for electro-
phoresis. After gel electrophoresis, the blots were transferred to
0.2 mm polyvinylidene ﬂuoride membranes, and the extraneous
proteins were blocked using 3% skimmilk as the blocking buffer for
1 hour. Then, primary antibodies to P2X3 (GeneTex, Irvine, CA,
USA), M2 (GeneTex), M3 (GeneTex), b3-AR (Abcam, Cambridge,
UK), and GAPDH (positive control; Cell Signaling Technology,
Danvers, MA, USA) were applied. The samples were incubated
overnight at 4C thenwashed with Tris-buffered saline with Tween
20 and incubated with secondary antibody (goat antirabbit
immunoglobulin G-HRP, 1:3000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The membranes were probed with enhanced
chemiluminescence reagent (ECL; Millipore Corporation, Billerica,
MA, USA) and exposed to X-ray ﬁlm.
2.6. Statistical analysis
The differences in the urodynamic parameters, urothelial
dysfunction, and sensory protein expressions between patients
with LUTDs and controls were analyzed using the KruskaleWallis
test. All calculations were performed using SPSS for Windows,
version 10.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was
considered statistically signiﬁcant.
3. Results
A total of 20 controls and 156 patients, including 14 with idio-
pathic OAB, 11 with DHIC, 19 with ESRD/HSB, 26 with SCI/neuro-
genic detrusor overactivity (NDO), 23 with BOO/DO, 19 with DM/
HSB, 20 with IC, and 24 with KC were investigated for urothelial
dysfunction and sensory protein expression. Table 1 lists the uro-
dynamic parameters. All patient subgroups had increases in
bladder sensation either at the ﬁrst sensation of ﬁlling or during
CBC testing, indicating bladder hypersensitivity in these patients.
All patients with BOO had DO. Patients with KC also presented with
very small CBC and DO. Additionally, the maximum ﬂow rate was
decreased in all subgroups, but the detrusor pressure was not
signiﬁcantly different from that of the controls, except in patients
with BOO. PVR volume was signiﬁcantly greater in patients with
DHIC, SCI, and IC, but was signiﬁcantly lower in patients with KC.
Table 2 provides the protein expressions in the urothelium of
the urinary bladder in patients with different LUTDs and controls.
All subgroups of patients had signiﬁcantly increased mast cell
activation and apoptotic cell counts in the urothelium, except for
DHIC. All subgroups had signiﬁcantly decreased E-cadherin
expression, except for ESRD/HSB. ZO-1 expressionwas signiﬁcantly
decreased in patients with ESRD/HSB, SCI/NDO, IC, and KC. P2X3
expression was signiﬁcantly decreased in DHIC but was signiﬁ-
cantly increased in patients with BOO/DO.
Confocal immunoﬂuorescence microscopy of the b3-AR in the
controls and patients with LUTDs is shown in Figure 1. The
immunohistochemistry results indicated that b3-AR was mainly
expressed in the urothelium. The apical surface of the urothelium in
particular had the highest expression. Suburothelial tissues express
lower levels of b3-AR.
Table 3 shows the expressions of muscarinic receptors M3, M2,
and b3-AR in the urothelium of the urinary bladder in patients with
LUTDs and controls. The urothelial M3 expression was signiﬁcantly
increased in patients with OAB, BOO/DO, DM/OAB, and KC. M2
expression was signiﬁcantly increased only in patients with BOO/
DO. b3-AR expression was signiﬁcantly increased in patients with
DHIC, ESRD/HSB, DM/OAB, and KC but was signiﬁcantly decreased
in patients with OAB. When we calculated the ratio of M3/b3-ARtion and sensory protein expressions in patients with urological or
http://dx.doi.org/10.1016/j.urols.2016.08.004
Table 2
Proteins expressed in the urothelium of the urinary bladder in patients with various LUTDs and the controls.
LUTD (n) E-Cadherin Mast cells TUNEL ZO-1 P2X3
Control (10)
OAB (14)
42.7 ± 20.3
24.8 ± 17.0*
3.99 ± 3.38
19.6 ± 5.0*
0.73 ± 0.97
5.62 ± 4.71*
11.0 ± 7.29
6.69 ± 5.02*
0.48 ± 0.42
0.47 ± 0.25
Control (10)
DHIC (11)
41.3 ± 8.4
15.4 ± 14.4*
5.9 ± 4.92
9.22 ± 4.38*
1.0 ± 1.35
6.55 ± 3.44*
6.37 ± 1.72
8.39 ± 4.67
1.66 ± 1.17
0.58 ± 0.54*
Control (10)
ESRD/HSB(19)
41.3 ± 8.4
27.1 ± 21.3*
5.9 ± 4.92
7.23 ± 5.10*
1.0 ± 1.35
3.15 ± 1.92*
6.37 ± 1.72
4.46 ± 3.84*
1.66 ± 1.17
1.04 ± 0.99
Control (10)
SCI/NDO (26)
42.4 ± 16.7
31.3 ± 19.8*
1.25 ± 1.15
16.5 ± 5.9*
0.08 ± 0.26
3.3 ± 2.14*
11.0 ± 5.66
6.50 ± 6.35*
1.66 ± 1.17
1.50 ± 0.73
Control (10)
BOO/DO (23)
27.7 ± 10.4
18.9 ± 13.6*
4.16 ± 2.68
16.1 ± 6.16*
0.85 ± 1.31
2.47 ± 2.41*
6.90 ± 1.82
7.29 ± 2.58
0.1 ± 0.12
0.25 ± 0.15*
Control (10)
DM/OAB (19)
42.7 ± 20.3
22.2 ± 15.1*
3.99 ± 3.38
23.3 ± 7.6*
0.73 ± 0.97
5.21 ± 5.63*
11.0 ± 7.29
11.2 ± 7.25
0.48 ± 0.42
0.62 ± 0.19
Control (19)
IC (20)
32.0 ± 13.0
21.3 ± 8.88*
6.96 ± 5.55
12.6 ± 8.37*
0.70 ± 1.07
1.86 ± 1.73*
5.69 ± 1.83
4.06 ± 3.56*
2.24 ± 2.70
2.07 ± 1.60
Control (10)
KC (24)
59.0 ± 19.6
12.5 ± 15.2*
2.78 ± 2.81
8.28 ± 5.56*
0.68 ± 0.62
3.63 ± 2.40*
13.3 ± 6.11
3.43 ± 5.00*
1.30 ± 0.16
1.42 ± 0.78
* Indicates signiﬁcant difference from the control.
BOO ¼ bladder outlet obstruction; DHIC: detrusor overactivity and inadequate contractility; DM ¼ diabetes mellitus; DO ¼ detrusor overactivity; ESRD: end-stage renal
disease, HSB ¼ hypersensitive bladder; IC ¼ interstitial cystitis; KC ¼ ketamine related cystitis; LUTD ¼ lower urinary tract disease; NDO ¼ neurogenic detrusor overactivity;
OAB ¼ overactive bladder; SCI ¼ spinal cord injury; TUNEL ¼ Terminal deoxynucleotidyl transferase dUTP nick end labeling; ZO-1 ¼ zonula occludens-1.
Table 1
Urodynamic parameters in patients with different LUTDs and controls.
LUTD (n) FSF
(mL)
CBC
(mL)
Pdet
(cmH2O)
Qmax (mL/s) PVR
(mL)
Control (10)
OAB (14)
180 ± 65.8
115 ± 54.0*
405 ± 113
240 ± 102*
24.4 ± 15.7
52.6 ± 33.6*
18.2 ± 11.6
9.0 ± 6.6*
51.8 ± 84
96 ± 92
Control (10)
DHIC (11)
179 ± 63.0
132 ± 58.4
412 ± 109
241 ± 121*
22.6 ± 14.3
19.8 ± 15.7
19.6 ± 11.6
3.0 ± 2.68*
44.7 ± 84.4
342 ± 127*
Control (10)
ESRD/HSB(19)
180 ± 65.8
154 ± 95.6
405 ± 113
224 ± 149*
24.4 ± 15.7
29.7 ± 20.2
18.2 ± 11.6
13.7 ± 11.1
51.8 ± 84.0
106 ± 177*
Control (10)
SCI/NDO (26)
179 ± 63.0
110 ± 60.1*
412 ± 109
290 ± 256*
22.6 ± 14.3
35.7 ± 23.3
19.6 ± 11.6
3.92 ± 4.75*
44.7 ± 84.4
230 ± 139*
Control (10)
BOO/DO (23)
180 ± 65.8
115 ± 54.0*
405 ± 113
285 ± 115*
24.4 ± 15.7
60.5 ± 33.4*
18.2 ± 11.6
7.74 ± 3.93*
51.8 ± 84
88.3 ± 89.9
Control (10)
DM/OAB (19)
180 ± 65.8
102 ± 62.4*
405 ± 113
276 ± 143*
24.4 ± 15.7
39.6 ± 21.6
18.2 ± 11.6
8.36 ± 3.13*
51.8 ± 84
76.3 ± 92.9
Control (10)
IC (20)
179 ± 63.0
152 ± 81.6
412 ± 109
284 ± 154*
22.6 ± 14.3
26.1 ± 13.6
19.6 ± 11.6
10.5 ± 8.02*
44.7 ± 84.4
59.3 ± 89.5
Control (10)
KC (24)
179 ± 63.0
18.1 ± 6.89*
412 ± 109
43.3 ± 15.7*
22.6 ± 14.3
24.3 ± 13.7
19.6 ± 11.6
6.87 ± 3.16*
44.7 ± 84.4
0.67 ± 2.58*
* Indicates signiﬁcant difference from the control.
BOO ¼ bladder outlet obstruction; CBC ¼ cystometric bladder capacity; DHIC ¼ detrusor overactivity and inadequate contractility; DM ¼ diabetes mellitus; DO ¼ detrusor
overactivity; ESRD ¼ end-stage renal disease, FSF ¼ ﬁrst sensation of ﬁlling; HSB ¼ hypersensitive bladder; IC ¼ interstitial cystitis; KC ¼ ketamine related cystitis;
LUTD ¼ lower urinary tract disease; NDO ¼ neurogenic detrusor overactivity; OAB ¼ overactive bladder; Pdet ¼ detrusor pressure at Qmax; PVR ¼ postvoid residual;
Qmax ¼ maximum ﬂow rate; SCI ¼ spinal cord injury.
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Patients with DHIC, ESRD/HSB, and SCI/NDO had signiﬁcantly
decreased M3/b3-AR and M2/b3-AR. Patients with BOO/DO had
signiﬁcantly decreased M3/b3-AR, but M2/b3-AR showed a signif-
icant increase. Patients with IC had signiﬁcant reductions, and KC
patients had signiﬁcant increases of M3/b3-AR.
4. Discussion
In several LUTDs and systemic diseases with bladder over-
activity or hypersensitivity, urothelial inﬂammation and functional
proteins showed signiﬁcant changes. The muscarinic receptors and
b3-AR and the ratio of M3/b3-AR and M2/b3-AR also showed al-
terations in certain diseases affecting bladder function. These
changes of urothelial expression contributed to sensory disorders
in the bladder storage phase and affected detrusor contractility.
In the patients with LUTDs and systemic diseases, bladder
inﬂammation and urothelial apoptosis increased. In previous
studies of IC, we demonstrated that inﬂammation led to increasedPlease cite this article in press as: Ong H-L, Kuo H-C, Urothelial dysfunc
systemic diseases and hypersensitive bladder, Urological Science (2016),urothelial apoptosis, which resulted in lower expression of the
adhesion protein E-cadherin and tight junction protein ZO-1.13
Additionally, chronic inﬂammation inhibited normal basal cell
proliferation and affected the apical urothelial function.13 Bladder
inﬂammation caused by intravesical irritants in patients with IC led
to intense afferent nerve activity and to long-term plasticity that
lowered the thresholds for nociceptive and mechanoceptive
afferent ﬁbers.32 Chronic inﬂammation is considered the primary
pathophysiology responsible for LUTS. Moreover, urinary nerve
growth factor is increased in patients with OAB, BOO, urinary tract
infection, IC, Parkinson's disease, and cerebrovascular accident.33 It
is possible that OAB symptoms are associated with chronic
inﬂammation of the bladder wall and impaired urothelial function.
In patients with OAB, DHIC, ESRD/HSB, SCI/NDO, BOO/DO, DM/
OAB, IC, and KC, we observed decreased E-cadherin expression in
the urothelium. In patients with OAB, ESRD/HSB, SCI/NDO, IC, and
KC, we observed decreased ZO-1 expression. Decreased E-cadherin
in the urothelium results in increased bladder pain scores in pa-
tients with IC.2 These urothelial dysfunctions could be associatedtion and sensory protein expressions in patients with urological or
http://dx.doi.org/10.1016/j.urols.2016.08.004
Figure 1. Confocal immunoﬂuorescence microscopy of the b3-adrenoceptors in the patients with (A) a normal bladder; (B) overactive bladder; (C) detrusor overactivity and
inadequate contractility; (D) end-stage renal disease and hypersensitive bladder; (E) spinal cord injury and detrusor overactivity; (F) bladder outlet obstruction and detrusor
overactivity; (G) diabetes mellitus and overactive bladder; (H) interstitial cystitis; and (I) ketamine cystitis. White lines represent basement membrane of the uroepithelium. Green
color indicates immunoﬂuorescent staining of the b3-adrenoceptors.
Table 3
Muscarinic receptor M3 and M2 and b3-AR adrenoceptor expression in the urothelium of the urinary bladder in patients with different LUTDs and controls.
LUTD (n) M3 M2 b3-AR M3/b3 M2/b3
Control (10)
OAB (14)
0.24 ± 0.23
0.90 ± 0.61*
0.31 ± 0.43
0.58 ± 0.68
0.37 ± 0.19
0.24 ± 0.25*
0.90 ± 1.36
9.83 ± 10.9*
0.87 ± 1.33
5.02 ± 4.93*
Control (10)
DHIC (11)
1.55 ± 1.03
0.82 ± 0.35
1.22 ± 0.59
0.56 ± 0.62*
0.57 ± 0.48
0.86 ± 0.30*
3.44 ± 2.28
1.08 ± 0.51*
4.03 ± 4.45
0.61 ± 0.57*
Control (10)
ESRD/HSB(19)
1.55 ± 1.03
1.57 ± 1.89
1.22 ± 0.59
1.61 ± 1.96
0.57 ± 0.48
1.55 ± 1.0*
3.44 ± 2.28
0.88 ± 0.70*
4.03 ± 4.45
0.85 ± 1.13*
Control (10)
SCI/NDO (26)
1.55 ± 1.03
0.37 ± 0.27
1.22 ± 0.59
0.79 ± 0.65
0.57 ± 0.48
0.78 ± 0.54
3.44 ± 2.28
0.69 ± 0.71*
4.03 ± 4.45
1.38 ± 1.35*
Control (10)
BOO/DO (23)
1.59 ± 0.70
0.70 ± 0.31*
0.41 ± 0.30
1.07 ± 1.18*
0.88 ± 0.58
0.86 ± 0.27
2.15 ± 1.42
0.86 ± 0.50*
0.61 ± 0.55
1.42 ± 1.65*
Control (10)
DM/OAB (19)
0.24 ± 0.23
0.84 ± 0.56*
0.31 ± 0.43
0.41 ± 0.59
0.37 ± 0.19
0.86 ± 0.66*
0.90 ± 1.36
3.06 ± 5.96*
0.87 ± 1.33
0.51 ± 0.46
Control (10)
IC (20)
1.92 ± 2.23
0.60 ± 0.32*
1.53 ± 1.83
1.13 ± 0.42
0.84 ± 1.10
0.70 ± 0.40
3.08 ± 1.82
1.64 ± 1.89*
3.72 ± 3.83
2.64 ± 2.67
Control (10)
KC (16)
0.14 ± 0.93
0.81 ± 0.46*
0.12 ± 0.21
0.18 ± 0.21
1.06 ± 0.13
2.41 ± 1.79*
0.12 ± 0.07
0.47 ± 0.38*
0.11 ± 0.18
0.12 ± 0.17
* Indicates signiﬁcant difference from the control.
BOO ¼ bladder outlet obstruction; DHIC: detrusor overactivity and inadequate contractility; DM ¼ diabetes mellitus; DO ¼ detrusor overactivity; ESRD: end-stage renal
disease, HSB ¼ hypersensitive bladder; IC ¼ interstitial cystitis; KC ¼ ketamine related cystitis; LUTD ¼ lower urinary tract disease; NDO ¼ neurogenic detrusor overactivity;
OAB ¼ overactive bladder; SCI ¼ spinal cord injury.
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estingly, the P2X3 expressions showed signiﬁcant increases only in
BOO/DO and decreases in DHIC, but no change in the other diseases,
suggesting the P2X3 expression in the urothelium is associated
with bladder sensation as well as detrusor contractility. During
bladder storage, ATP is released from the urothelial cells triggering
bladder fullness sensations or inducing bladder activity.21 In pa-
tients with DHIC, the decrease in P2X3 receptors could diminish the
trigger effect on sustained detrusor contraction, resulting in large
PVR volumes and poor bladder sensation when the bladder is not
completely emptied.
b3-AR is expressed strongly in the umbrella cells compared to
cells in the intermediate urothelial layers.29 Stimulation of b3-AR
relaxes detrusor smooth muscle, decreases afferent signaling from
the bladder, and improves bladder compliance, thus increasing
bladder capacity.34 Unlike themechanism of antimuscarinic agents,
b3-AR agonists increase bladder capacity without accompanying
changes in micturition pressure, PVR volume, or voiding contrac-
tion.35 Normal bladder sensation is important in the initiation of
the detrusor reﬂex during voiding and sustained detrusor
contractility during voiding. b3-AR agonists could stimulate the
urothelial release of unidentiﬁed factors that inhibit detrusor
contractility directly or indirectly.36 Stimulation of M2 receptors
could inhibit sympathetic b-AR-mediated relaxation, leading to
more efﬁcient bladder emptying.37 Both muscarinic receptors and
b3-AR are involved in the urotheliogenic signaling on enhancing or
inhibiting detrusor contractility.34,36 If the mucosal expressions of
these receptors are inadequate, patients might have altered bladder
sensation or inadequate bladder emptying.
Both M3 and M2 receptors are highly expressed in the urothe-
lium of the bladder.15 The functional role of M2 receptors may
emerge and increase in density in certain bladder diseases, such as
BOO in rats,38 neurogenic bladder disease in humans,39 and
denervated bladder disease in rats.40 In addition, muscarinic re-
ceptors in the urothelium or suburothelium may affect sensory ﬁ-
bers and contribute to the pathophysiology of OAB.16,41
Acetylcholine released from parasympathetic postganglionic neu-
rons or nonneuronal sources, such as the urothelium and sub-
urothelium during bladder ﬁlling, stimulates subsequent
micromotion in the detrusor resulting in afferent stimulation,
which contributes to the pathophysiology of OAB.19,42
In this study, urothelial M2 and M3 receptors were signiﬁcantly
increased in patients with OAB and BOO/DO but were decreased in
patients with DHIC and SCI/NDO. b3-AR expression was signiﬁ-
cantly decreased in patients with OAB, but signiﬁcantly increased in
patients with DHIC, ESRD, and DM/OAB; the change in b3-AR
density could be related to low voiding efﬁciency and large PVR
volume in these diseases. When we calculated the M3/b3-AR and
M2/b3-AR ratios, only patients with OAB had increases in both
ratios. Patients with BOO/DO had lower M3/b3-AR than patients
with OAB, but M2/b3-AR was signiﬁcantly increased. Patients with
DHIC, SCI/NDO, and ESRD/HSB all showed signiﬁcant decreases in
both ratios. An imbalance of urothelial M3, M2 receptors, and b3-
AR is associated with OAB. In patients with BOO/DO, the increase
in expression of urothelial M2 was greater than that of M3 re-
ceptors, without a change in b3-AR and resulting in DO. In patients
with lowM3/b3-AR and M2/b3-AR in the urothelium, poor voiding
efﬁciency and large PVR volumes were noted, which could be
attributed to decreased muscarinic stimulation in association with
an increase in b3-AR density.
We also found M3 receptors and M3/b3-AR increased in KC and
decreased in IC. The increase of M3/b3-AR in KC bladders might be
associated with more detrusor overactivity and smaller CBC in KC
patients than those in IC bladders. Patients with IC or KC could have
denuded urothelium resulting in inconsistent protein expressionsPlease cite this article in press as: Ong H-L, Kuo H-C, Urothelial dysfunc
systemic diseases and hypersensitive bladder, Urological Science (2016),based on observations of the bladder biopsy samples. Nevertheless,
severe inﬂammation and urothelial dysfunction were evident in
both IC and KC patients, which could have led to increased bladder
sensation and small bladder capacity.
The strength of this study was the use of multiple LUTD with
hypersensitive bladder to investigate the urothelial dysfunction
and sensory protein expressions in human bladders. However, the
limitation of the study is the small case number in each LUTD
subgroup that may have wide variations in clinical and urothelial
characteristics.
5. Conclusion
Patients with LUTDs and nonurological diseases and bladder
overactivity or hypersensitivity showed increased urothelial
inﬂammation and lower barrier protein expressions. The urothelial
muscarinic receptors and b3-AR expression were also altered.
Increased M3/b3-AR or M2/b3-AR is associated with OAB, whereas
decreased M3/b3-AR or M2/b3-AR is associated with poor voiding
efﬁciency and large PVR volume. Treatment of bladder hypersen-
sitivity or low voiding efﬁciency in these LUTDs might target the
altered receptor ratio.
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